1. Use of recombinant factor VIIa (NovoSeven) in a haemophilia A patient with inhibitor in Kuwait
- Author
-
Kanyike Fb, Sharhan A, Prakash B, Youssef Ah, Wahib N, and Abdul-Salam Sa
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Haemophilia A ,Hematology ,General Medicine ,medicine.disease ,Haemophilia ,Gastroenterology ,Surgery ,Coagulation ,Recombinant factor VIIa ,hemic and lymphatic diseases ,Internal medicine ,medicine ,biology.protein ,High doses ,In patient ,Bypassing agent ,business ,Complication ,Genetics (clinical) - Abstract
Development of inhibitors is a known complication in some haemophiliacs receiving coagulation factor replacement therapy. We report on the successful management of a young boy with haemophilia A with inhibitor using recombinant factor VIIa. We had failed to control bleeding in this patient following his circumcision, despite infusion with high doses of factor VIII concentrate for 2 weeks. Recombinant factor VIIa is a useful ‘factor VIII bypassing agent’ for the control of bleeding in patients with haemophilia A and B who develop inhibitors. We suggest that severely affected haemophiliacs should be absolved of ritual circumcision as a protective measure against what might become a life-threatening haemorrhage – especially in those with inhibitors.
- Published
- 1999
- Full Text
- View/download PDF